Bicara Therapeutics: Funding, Investors & Team (Oct 2026)
Bicara Therapeutics, a company owned entirely by Biocon and located in Boston, USA, is currently working on a series of bifunctional antibodies that make use of the latest immuno-oncology advancements. Bicara benefits from access to the thriving US innovation ecosystem, which hastens the development of advanced cancer therapies. The scientific teams in Boston and Bengaluru will collaborate to pioneer groundbreaking innovation that is both speedy and cost-effective.
Bicara Therapeutics has raised $298M across 3 funding rounds on record, the most recent an undisclosed round of $150M announced in Feb 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bicara Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Bicara Therapeutics Funding Rounds
Bicara Therapeutics raised $40.0M in a Seed announced in Mar 2021.
2 years later, a Series B of $108M was announced in Mar 2023.
2.9 years later, an undisclosed round of $150M was announced in Feb 2026.
Bicara Therapeutics Founders and Leadership Team
Contact details for the Bicara Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bicara Therapeutics Funding Compared to Other Biotechnology Startups
Bicara Therapeutics' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bicara Therapeutics in Biotechnology and Cambridge
Companies Similar to Bicara Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Bicara Therapeutics Funding FAQs
What does Bicara Therapeutics do?
Bicara Therapeutics, a company owned entirely by Biocon and located in Boston, USA, is currently working on a series of bifunctional antibodies that make use of the latest immuno-oncology advancements. Bicara benefits from access to the thriving US innovation ecosystem, which hastens the development of advanced cancer therapies. The scientific teams in Boston and Bengaluru will collaborate to pioneer groundbreaking innovation that is both speedy and cost-effective.
How much funding has Bicara Therapeutics raised?
Bicara Therapeutics has raised $298M across 3 rounds on record. The most recent is an undisclosed round of $150M announced in Feb 2026.
When did Bicara Therapeutics last raise funding?
Bicara Therapeutics' most recent funding round on record is an undisclosed round of $150M, announced in Feb 2026.
Who is the CEO of Bicara Therapeutics?
Claire Mazumdar is listed as CEO at Bicara Therapeutics.
Where is Bicara Therapeutics headquartered?
Bicara Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Bicara Therapeutics have?
Bicara Therapeutics is in the 101-250 employee band.
How does Bicara Therapeutics' funding compare to other Biotechnology startups?
Bicara Therapeutics' latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Bicara Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bicara Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.